Pericarditis secondary prevention
|
Pericarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Surgery |
|
Case Studies |
|
Pericarditis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Pericarditis secondary prevention |
|
Risk calculators and risk factors for Pericarditis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2] Hafiz M. Ahmed, M.D.[3]
Overview
Secondary prevention of pericarditis focuses on reducing the risk of recurrence after an initial episode. The cornerstone of secondary prevention is the addition of colchicine to NSAID or aspirin therapy during the first episode, which has been shown to reduce recurrence rates by approximately 50%. Additional strategies include CRP-guided tapering of anti-inflammatory medications, avoidance of corticosteroids as first-line therapy (which are associated with increased recurrence risk), and exercise restriction during the acute phase. For patients with recurrent disease despite first-line therapy, anti-IL-1 agents (anakinra, rilonacept, goflikicept) are the preferred escalation therapy for those with an inflammatory phenotype.
Secondary Prevention
Effective measures for the secondary prevention of pericarditis include [1]:
Colchicine as Adjunctive First-Line Therapy
- The single most important secondary prevention measure is the addition of colchicine to NSAID or aspirin therapy during the initial episode. Colchicine 0.6 mg twice daily (or 0.6 mg once daily for patients weighing less than 70 kg or with renal/hepatic impairment or gastrointestinal intolerance) for 3 months during a first episode reduces the recurrence rate from approximately 26% to 14%. For recurrent episodes, colchicine should be continued for at least 6 months.
CRP-Guided Tapering of Anti-Inflammatory Therapy
- C-reactive protein (CRP) should be monitored to guide the duration of therapy and the pace of medication tapering. Anti-inflammatory medications should not be discontinued until symptoms have resolved and CRP has normalized. Tapering should be gradual, reducing one drug class at a time, rather than abrupt discontinuation. Premature tapering or abrupt cessation of therapy is a common cause of recurrence.
Avoidance of Corticosteroids as First-Line Therapy
- Corticosteroids should not be used as first-line therapy for acute pericarditis. Observational data suggest that early corticosteroid use during a first episode is associated with a higher rate of recurrence. When corticosteroids are necessary (such as for autoimmune disease or failure of NSAIDs and colchicine), they should be used at the lowest effective dose (prednisone 0.2 to 0.5 mg/kg/day) and tapered very slowly over months.
Exercise Restriction
- Exercise restriction for at least 1 month following a pericarditis episode or flare is recommended, keeping maximal heart rate below 100 beats per minute regardless of the type of physical activity. Increased heart rate enhances friction between inflamed pericardial layers, which may perpetuate inflammation and increase the risk of recurrence. Return to full activity should be guided by symptom resolution and CRP normalization.
Anti-IL-1 Therapy for Recurrence Prevention
- For patients who develop recurrent pericarditis despite dual therapy with NSAIDs and colchicine, anti-IL-1 agents are the preferred escalation therapy when an inflammatory phenotype is present (elevated CRP greater than 1 mg/dL). Three agents have been studied: anakinra (1 to 2 mg/kg/day subcutaneously), rilonacept (320 mg loading then 160 mg weekly subcutaneously, FDA-approved for recurrent pericarditis), and goflikicept (80 mg subcutaneously every 2 weeks). Recurrence rates are very low while on anti-IL-1 therapy but approximately 50% to 75% of patients experience recurrence upon discontinuation, so treatment duration of more than 12 months is generally recommended.
Avoidance of Known Triggers
- Patients should be counseled to avoid premature return to strenuous physical activity and to complete the full prescribed course of anti-inflammatory therapy. Dose reductions or discontinuation of colchicine should be guided by clinical remission and CRP normalization rather than symptom improvement alone.
Referral for Refractory Disease
- Patients with multiple recurrences despite optimal medical therapy should be referred to a multidisciplinary Pericardial Diseases Center for consideration of advanced therapies including anti-IL-1 agents, immunosuppressive agents (azathioprine, IVIG), or radical pericardiectomy as a last resort.
References
- ↑ Wang, T. K. M., Klein, A. L., Cremer, P. C., Imazio, M., Kohnstamm, S., Luis, S. A., Mardigyan, V., Mukherjee, M., Ordovas, K., Vakamudi, S., & Wohlford, G. F. (2025). 2025 concise clinical guidance: An ACC expert consensus statement on the diagnosis and management of pericarditis: A report of the American college of cardiology solution set oversight committee. Journal of the American College of Cardiology, 86(25), 2691–2719. https://doi.org/10.1016/j.jacc.2025.05.023